Both in Pharmaceuticals
uniQure vs Ocular Therapeutix
Over the past year QURE returned −62.4% and OCUL returned −42.0%; their daily moves had a correlation of 0.02.
QURE −62.4% OCUL −42.0%Growth of $1, one year, split-adjusted
| Metric | QURE | OCUL |
|---|---|---|
| Price | $21.78 | $6.87 |
| Market cap | $1.51B | $1.51B |
| Today | −3.29% | −6.91% |
| 1 month | −50.6% | −32.2% |
| 6 months | +23.9% | −30.0% |
| Year to date | −9.0% | −43.4% |
| 1 year | −65.3% | −42.4% |
| Revenue growth (YoY) | +11.0% | +0.1% |
| Gross margin | 94.0% | 85.1% |
| Net margin | −1387.8% | −584.5% |
| P/E (TTM) | — | — |
| Price / sales | 80.9× | 29.0× |
| Net cash | $760.2M | $525.8M |
| Dividend yield | — | — |
| Volatility (60d) | 107.4% | 71.0% |
| Short % of float | 13.2% | 15.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).